BIIB Q2 2017 Earnings — Biogen Inc. Revenue & Financial Results | Market Cap Arena

BIIBBiogen Inc.

$28B

Q2 2017 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$3.1B+6.4% YoY

Gross Profit

$2.7B88.1% margin

Operating Income

$1.2B39.0% margin

Net Income

$863M28.0% margin

EPS (Diluted)

$4.07

QoQ Revenue Growth

+9.5%

Cash Flow

Operating Cash Flow

$1.2B

Free Cash Flow

$846M

Stock-Based Comp.

$34M

Balance Sheet

Total Assets

$21.8B

Total Liabilities

$10.2B

Stockholders' Equity

$11.6B

Cash & Equivalents

$1.2B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.1B	$2.9B	+6.4%
Gross Profit	$2.7B	$2.5B	+7.5%
Operating Income	$1.2B	$1.5B	-17.8%
Net Income	$863M	$1.0B	-17.8%

Revenue Segments

Hemophilia Products

$74M100%